These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19753589)

  • 21. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
    Enjoji M; Dainichi T; Gondo H; Urabe K
    Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
    J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C.
    Ishikawa T; Kubota T; Abe H; Hirose K; Nagashima A; Togashi T; Seki K; Honma T; Yoshida T; Kamimura T
    Hepatogastroenterology; 2012 Oct; 59(119):2260-3. PubMed ID: 23435141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
    J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interstitial pneumonitis during combination therapy with interferon-alpha and ribavirin in a patient with chronic Hepatitis C.
    Rothfuss KS; Bode JC
    Z Gastroenterol; 2002 Sep; 40(9):807-10. PubMed ID: 12215950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: a case report.
    Baik SJ; Kim TH; Yoo K; Moon IH; Cho MS
    World J Gastroenterol; 2012 Aug; 18(31):4233-6. PubMed ID: 22919260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
    Yang WS; Chu PL; Liu CH; Chung GB; Wu KD
    J Clin Gastroenterol; 2008 Jan; 42(1):112-3. PubMed ID: 18097301
    [No Abstract]   [Full Text] [Related]  

  • 28. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
    Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 32. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection.
    Schreuder TC; Gelderblom HC; Weegink CJ; Hamann D; Reesink HW; Devries JH; Hoekstra JB; Jansen PL
    Liver Int; 2008 Jan; 28(1):39-46. PubMed ID: 18031478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of sarcoidosis during interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature.
    Bolukbas C; Bolukbas FF; Kebdir T; Canayaz L; Dalay AR; Kilic G; Ovunc O
    Acta Gastroenterol Belg; 2005; 68(4):432-4. PubMed ID: 16432996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature.
    López V; Molina I; Monteagudo C; Jordá E
    Int J Dermatol; 2011 Mar; 50(3):287-91. PubMed ID: 21342161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis.
    Sabbatani S; Manfredi R; Marinacci G; Pavoni M; Cristoni L; Chiodo F
    Scand J Infect Dis; 2006; 38(3):205-8. PubMed ID: 16500782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
    Testino G; Gentile R; Ansaldi F; Borro P; Ravetti G; Icardi G; Sumberaz A
    Panminerva Med; 2009 Jun; 51(2):135-6. PubMed ID: 19776716
    [No Abstract]   [Full Text] [Related]  

  • 37. New-onset psoriasis following treatment with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C.
    Horev A; Halevy S
    Isr Med Assoc J; 2009 Dec; 11(12):760-1. PubMed ID: 20166347
    [No Abstract]   [Full Text] [Related]  

  • 38. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.
    Yu ML; Dai CY; Lee LP; Hsieh MY; Hou NJ; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Antivir Ther; 2006; 11(8):1015-9. PubMed ID: 17302371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C.
    Fontana RJ; Bieliauskas LA; Lindsay KL; Back-Madruga C; Wright EC; Snow KK; Lok AS; Kronfol Z; Padmanabhan L;
    Hepatology; 2007 May; 45(5):1154-63. PubMed ID: 17465000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
    Crespo M; Mira JA; Pineda JA; Van den Eynde E; Ríos-Villegas MJ; Collado A; Girón-González JA; López-Cortés LF; González-Serrano M; Rivero A; Merino D; Esteban JI
    J Antimicrob Chemother; 2008 Oct; 62(4):793-6. PubMed ID: 18567911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.